Biotech Values

[drbio45]

When a company has a garbage drug but raises over a hundred million dollars a year they get analyst coverage


Bank of America Merrill Lynch Steve Byrne, CFA
Barclays Capital Jim Birchenough, M.D.
BMO Capital Markets Jason Zhang, Ph.D.
Canaccord Adams Adam Cutler
Cowen & Co. Phil Nadeau, Ph.D.
CRT Capital Group Leah A. Hartman
Davenport & Company Joel M. Ray, CFA
Hapoalim Securities Jon LeCroy, M.D.
Jefferies & Company Thomas Wei
JMP Securities Jason N. Butler, Ph.D.
JPMorgan Cory Kasimov
Lazard Capital Markets William Tanner, Ph.D.
Leerink Swann and Co. Steve Y. Yoo
Needham & Company Alan Carr
Oppenheimer & Co. Bret Holley, Ph.D.
Piper Jaffray Edward A. Tenthoff
Rodman and Renshaw Elemer Piros, Ph.D.
Summer Street Research Partners Carol Werther
UBS Jeff Elliott, Ph.D.
Wells Fargo Securities Aaron S. Reames

pretty unbelieveble